In the current issue Lin et al. present the results of their study investigating the technical feasibility of a "cocktail" PET imaging approach whereby 18 F-FDG and NaF were injected simultaneously (85%) or sequentially on the same day (15%). Compared with the FDG studies performed independently, the authors report improved sensitivity for detection of osseous metastatic lesions, nearly comparable soft tissue lesion detection, more efficient patient throughput, and reduced radiation exposure from the CT component of the simultaneous examination. The authors conclude that "cocktail" PET imaging is technically feasible; that is, it can be done using existing equipment [1] .
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A separate consideration, however, is the clinical applicability of this technique. While the "cocktail" approach may be technically feasible, one can identify several potential concerns regarding the utility of this approach and scenarios in which it may be of limited utility or even potentially hazardous. A few of these concerns are as follows:
1. Which (if any) patients clinically require both FDG and NaF imaging on an a priori basis (i.e., without knowing the results of one study before proceeding to the other), and how does this approach fit into the context of evidence-based clinical practice guidelines? Bone scans have historically been performed in many cancers (most notably prostate and breast) as an adjunct to anatomic imaging modalities such as CT which image a limited body region and have relatively poor sensitivity for detection of osseous metastases. This approach is changing in the modern era of molecular imaging and "whole-body" PET imaging. For many cancers the sensitivity for osseous metastatic lesion detection with FDG alone is reasonable and, in many cases, adequate for accurate staging. In the authors' current data, 57/62 patients (92%) were accurately M-staged with FDG PET alone; of the remaining 5/62 patients (8%) for whom the addition of NaF changed staging from M0 to M1, the number with prostate cancer (for whom FDG staging is known to be unreliable) was not specified. That NaF identifies more osseous lesions is not surprising, but the detection of more bony lesions in a patient already established to have osseous M1 disease is often not clinically relevant.
Current oncologic practice guidelines (e.g., NCCN in the USA) already reflect this consideration. NCCN clinical practice guidelines currently exist for 33 major cancer types. Of these 33 cancer types, bone scan is not recommended at all in 22. In the remaining 11 cancer types bone scan is recommended in selected clinical situations, but in no cancer type are both bone scan and FDG PET recommended to be performed together on an a priori basis (with the exception of osseous sarcomas in which the recommendation is for FDG PET and/or bone scan). With this in mind, the cocktail approach might potentially increase radiation exposure if the bone scan component provides minimal additional data of clinical relevance compared with the FDG scan alone.
2. In what scenarios does the inability to differentiate the FDG and NaF datasets confound (rather than enhance) image interpretation? Unlike dual isotope single-photon imaging in which signals from tracers of different photon energies can be discriminated, PET tracers emit photons of identical energy such that the relative contributions of each tracer cannot be differentiated. In the initial staging setting where the intent is typically to detect as many lesions as possible (regardless of whether they are FDG-and/or NaFavid), this issue may be irrelevant. However, in the posttreatment setting, the inability to differentiate FDG and NaF data may be problematic since bone scans most often normalize much more slowly than FDG scans. As a result, most early imaging assessment for treatment response does not rely on bone scanning, and thus the "cocktail" approach may be of limited clinical utility after initial staging since it may potentially obscure assessment of treatment response. Furthermore, comparing a posttreatment FDG-only scan to a baseline FDG/NaF "cocktail" scan (where the relative contributions of each tracer are not differentiable) may be challenging or potentially misleading.
3. Does the FDG/NaF "cocktail" approach reduce overall diagnostic specificity of the combined study? As expected, this study found increased sensitivity for detection of osseous lesions by adding NaF to the FDG study. However, the current article does not directly address specificity. Bone imaging (with NaF or single-photon agents) is well known to be nonspecific (compared to FDG imaging); e.g., degenerative, posttraumatic, and other benign processes are typically more conspicuous on NaF imaging than FDG imaging. While biopsy of every skeletal lesion would be clinically impossible, one could theorize that the addition of NaF to the FDG study may reduce overall diagnostic specificity by increasing false positive bone findings. Specificity might be improved by utilizing the CT component of the examination, but the authors did not address the CT images in this study.
4. How does the "cocktail" technique affect image quantitation? The current article does not address potential effects on quantitative or semiquantitative parameters (SUV), but intuition suggests that such parameters may not be directly comparable to the component scans performed separately. This would need to be rigorously studied and may become a more important consideration as image quantitation evolves, as response criteria increasingly rely on quantitative or semiquantitative analysis, and as clinical trials increasingly rely on image quantitation. The optimal FDG:NaF dose ratio may play some role in this regard and would need further investigation as well.
The FDG/NaF "cocktail" technique is scientifically intriguing and the authors make a compelling argument for its technical feasibility-i.e., that it can be done. However, this article does not clearly address the question as to whether or not this technique should be done from a clinical applicability standpoint. Prior to generalized clinical adoption of this technique, the appropriate clinical applications and limitations of this approach should be more clearly defined. While the clinical utility or necessity of this technique may ultimately be limited, I applaud the authors for publicizing the concept of "cocktail" PET imaging since it may potentially hold greater promise for tracer combinations other than FDG and NaF.
